Treatment of Limited Stage (Stage I–II) Mantle Cell Lymphoma

Limited-stage mantle cell lymphoma — confined to stage I or stage II — is an uncommon presentation, accounting for a small minority of newly diagnosed MCL cases. Management differs meaningfully from advanced-stage disease and depends on individual risk features.

Clinical scenario

Limited stage (stage I–II) MCL is rare, forming 5%–15% of all newly diagnosed cases. The approach to treatment is stratified by risk level and disease extent within this limited-stage group, making careful risk assessment central to the management decision.

Treatment approach

The choice of treatment depends on the risk profile at presentation. For the lowest-risk stage I patients, a conservative local approach — including the option of observation — may be appropriate. As risk or tumour burden increases, additional modalities come into consideration, with the most intensive approach reserved for those with high-risk stage II features. Full protocol details, criteria, and regimen specifics →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/hem3.70233

Limited stage (stage I–II) MCL is rare, forming 5%–15% of all newly diagnosed cases.

In low‐risk disease (stage I, without risk factors), observation or ISRT can be offered [II, B].

Involved site radiotherapy (24–36 Gy) is associated with high response rates and remissions may be durable, albeit mostly in stage I disease and low‐risk MIPI groups.

In patients with intermediate risk/tumor load, a shortened systemic therapy, followed by radiation, may be considered [IV, B].

In stage II with high‐risk features, systemic treatment as per advanced stage is recommended [IV, B].

View source ↗